126 results about "Reperfusion Damages" patented technology

APRIL research shows that in a selected stroke patient, infusion of 0.2 mg / kg of ApTOLL (SEQ ID NO: 1) in combination with intravascular treatment is safe, and the death rate of 90 days is reduced. ApTOLL has proved to limit intracranial hemorrhage and reperfusion injury which may occur after recanalization, and also improve early nerve injury and long-term disability. ApTOLL molecules are provided for reducing the risk of intracranial or secondary bleeding after acute ischemic stroke, reducing nerve injury, and improving nerve recovery in a subject.

The invention relates to a method for constructing a myocardial ischemia reperfusion injury model, which comprises the following steps of: inserting a vascular occlusion body into a blood vessel of a target mouse, sending the vascular occlusion body to a coronary artery position where vascular occlusion is to be formed, and blocking the coronary artery position where vascular occlusion is to be formed by adopting the vascular occlusion body, the vascular occlusion body is partially or completely made of biodegradable materials, and myocardial ischemia reperfusion injury is simulated through degradation and penetration of the vascular occlusion body in a target mouse body. The vascular occlusion body is prepared from the biodegradable material, the biodegradable material can be automatically degraded in an animal body, myocardial ischemia reperfusion can be simulated without additional operation, and myocardial ischemia reperfusion can be simulated by setting different thicknesses of the degradable part of the vascular occlusion body. The coronary artery ischemia reperfusion time is accurately controlled, and the controllability of the reperfusion time is improved, so that the disease progress of myocardial ischemia / acute myocardial infarction of a human body and reperfusion injury are accurately simulated.

The invention discloses an application and method of SAH-CIM hydrogel in promoting survival of retinal ganglion cells in glaucoma. The hydrogel comprises a Y-type primitive composed of three DNA chains and a siRNA connector, and the nucleotide sequences of the three DNA chains are SEQ ID NO.1-SEQ ID NO.3; the method comprises the following steps: S1, constructing a Y-type primitive: mixing three DNA chains with equal molar concentration in an annealing buffer solution, performing high-temperature denaturation at 95 DEG C, and then quickly cooling to 4 DEG C to finish annealing, so as to form a stable Y-type structure with three-way cohesive ends; s2, synthesizing a siRNA (small interfering Ribonucleic Acid) connector; and S3, mixing the Y-type element and the siRNA connector according to a molar ratio of 1: 1.5 at room temperature to react for 30 minutes, and forming a three-dimensional network structure through complementary pairing driven self-assembly, thereby finally obtaining the SAH-CIM hydrogel. The SAH-CIM hydrogel provided by the invention can be used for preventing / treating ischemia-reperfusion injury and related diseases, for example, the SAH-CIM hydrogel can be used for treating glaucoma, accurate co-delivery of a neuroprotective agent and an immunomodulator can be realized, and the SAH-CIM hydrogel has the advantages of treatment accuracy and biocompatibility.

The invention discloses a bionic bacterial outer membrane nano-particle for drug delivery. The bionic bacterial outer membrane nano-particle is characterized by comprising low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out, and low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out; the medicine carrying liposome is prepared from phosphatidylcholine, cholesterol and DSPE-PEG2000 (Distearoyl Phosphatidylcholine-Polyethylene Glycol 2000) according to a preset mass ratio; the low-toxicity outer membrane vesicles and the drug-loaded liposome are subjected to ultrasonic assistance and 100nm filter membrane extrusion to obtain bionic bacterial outer membrane nanoparticles, the average particle size of the bionic bacterial outer membrane nanoparticles is about 100nm, and the encapsulation efficiency exceeds 85%. The BM-NPs system disclosed by the invention can load small molecule compounds, proteins, nucleic acids and gene therapy vectors, and is suitable for various central nervous system diseases such as spinal cord injury, cerebral apoplexy, traumatic brain injury, ischemia-reperfusion injury and the like.

The invention belongs to the field of traditional Chinese medicine chemistry and natural product separation, and particularly relates to extraction and separation of a novel triterpenoid compound 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol and application of the novel triterpenoid compound 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol in myocardial protection drugs. The compound is named as 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol, and the structural formula of the compound is shown in the description. The invention provides an extraction and separation method of the compound. The extraction and separation method mainly comprises the following steps: sequentially carrying out solvent extraction, macroporous adsorption resin enrichment, silica gel column chromatography, ODS medium-pressure column chromatography, high performance liquid chromatography separation and purification and the like on ginseng and other traditional Chinese medicine processed products and hydrolysates. The structure of the compound is determined through comprehensive analysis of a high-resolution mass spectrum (HRMS), one-dimensional nuclear magnetic resonance (1H NMR, 13C NMR) and a two-dimensional nuclear magnetic resonance spectrum (such as HSQC, HMBC, ROESY and the like), and the compound is a newly discovered dammarane type triterpene compound. Experiments show that the compound and the composition thereof have a remarkable protection effect on myocardial cell hypoxia / reoxygenation reperfusion injury, and can be used for preparing drugs for preventing or treating myocardial ischemia reperfusion injury and other related diseases.

The invention discloses an NLRP3 inhibitor as well as a preparation method and application thereof. Specifically, the invention relates to a compound shown as a formula (NLRP3i-3) or a pharmaceutically acceptable salt thereof, the formula (I) is COCCNc1nc2c (c (= O) n (C) c (= O) n2C) n1Cc1cc (OC) ccc1N, and the chemical name is 8-((4-amino-2-methoxybenzyl)-7, 9-dimethyl-7, 9-dihydro-8H-purine-6, 8-diketone. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and application of the compound in preparation of drugs for preventing and / or treating NLRP3-mediated diseases. The disease is preferably myocardial ischemia reperfusion injury. Experimental results show that the compound provided by the invention has excellent NLRP3 inhibitory activity (IC50lt, 100nM), and has high selectivity to NLRP3 inflammasomes; good pharmacokinetic characteristics are achieved in a rat body, and the bioavailability is high; in myocardial ischemia reperfusion injury models of mice and rats, the composition can significantly reduce myocardial infarction area, reduce myocardial enzyme level, alleviate inflammatory response and improve heart function; preliminary toxicological evaluation shows that the safety is good. Therefore, the compound disclosed by the invention is expected to be developed into a novel medicine for treating NLRP3 related diseases such as myocardial ischemia-reperfusion injury.

A method of treating reperfusion injury in a tissue of a subject in need thereof. The method includes applying light, to the tissue, that inhibits electron transfer from cytochrome c to cytochrome c oxidase (CcO) to molecular oxygen to attenuate creation of reactive oxygen species. The light includes wavelengths in a first wavelength range of 730-770 nm and a second wavelength range of 930-970 nm.

The invention discloses an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury, relates to the technical field of biological medicines, and particularly relates to an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury. The resveratrol is used for preparing the medicine for treating the pulmonary ischemia reperfusion injury, and the resveratrol in the medicine inhibits cell apoptosis by activating an RSPO3 / Wnt / beta-catenin signal channel, so that the pulmonary ischemia reperfusion injury is relieved; the resveratrol in the medicine can relieve the pulmonary ischemia reperfusion injury by inhibiting apoptosis of alveolar macrophages induced by hypoxia / reoxygenation; the conditions for inhibiting apoptosis induced by hypoxia / reoxygenation by adopting resveratrol are as follows: the resveratrol with the concentration of 2.5 mu M is adopted to pretreat macrophages; the resveratrol plays a protection role by activating an RSPO3 / Wnt / beta-catenin signal channel, and a new basis is provided for the medical application; the resveratrol is applied to preparation of the medicine for treating the lung ischemia-reperfusion injury, cell apoptosis is inhibited, and lung tissue injury is relieved.

The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of extracellular histone mediated ailments in subjects.

The present disclosure relates to a method for reducing or hindering development of renal ischemia-reperfusion injury in a subject the method comprising administering an antibody that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation.

A device comprising interconnected components for deoxygenating blood used in the treatment and prevention of reperfusion injury, including a configuration to reduce the ionized calcium concentration of the deoxygenated blood to less than 0.5 mmol / L. The components may include a syringe pump operably communicating with various configurations via a control unit / processor, a cannula, a pump communicating with the cannula, a heat exchanger, a device for generating / creating fluid flow, an infusion port, a mixing port, a device hub, and a catheter hub. These components are selectively connected to a subject, and monitoring and / or other lead wires / devices may be attached to the subject. The lead wires / devices may include sensors and other devices that can be attached to / connected to the subject, providing health indicators, such as a temperature sensor, electrodes for monitoring cardiac electrical activity, and an oxygen saturation (SpO2) sensor for monitoring the patient's blood oxygen saturation.

A family of bioactive compounds identified in self-resolving inflammatory exudates is disclosed. The compounds give UV chromophores characteristic of a conjugated triene double bond system coupled to an auxochrome allylic to the triene. Further elucidation of the compounds reveals that they have a resolvin backbone conjugated to a peptide or amino acid moiety via an auxochrome. In some embodiments the auxochrome is sulfur. However, the auxochrome may be NH, CH2 or O. The compounds have potent bioactivity, in vitro, and, in vivo, including promoting resolution of infection, stimulating macrophage phagocytosis of bacteria; protecting tissues from neutrophil mediated damage, promoting tissue repair and regeneration and preventing or limiting second organ reflow / reperfusion damage.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The application relates to a dual-purpose maintenance system for taking out a heart and maintaining the heart extracorporeally, which comprises a perfusion pipeline assembly and an organ box. The design that the organ box is communicated with a blood storage container and is switched can support the no-stop-taking-out and transportation operation of the heart. In the conversion process, the pipeline does not need to be replaced, the heat ischemic injury and ischemia-reperfusion injury of the heart are reduced.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of a transcription factor ZHX2 in diagnosis and treatment of hepatic ischemia-reperfusion injury. Specifically, research finds that the expression of ZHX2 after ischemia reperfusion injury is reduced, and HIRI cell necrosis and generation and development of HIRI are obviously promoted by specifically knocking out Zhx2 from liver cells, which are further proved in marginal liver IRI, while the ZHX2 has a protective effect on marginal fatty liver ischemia reperfusion injury. In conclusion, the ZHX2 can be used as a biological marker and a related treatment target of the hepatic ischemia reperfusion injury, especially marginal hepatic ischemia reperfusion injury, so that the ZHX2 has good clinical application value and social benefit.

The present invention relates to pharmaceutical compositions and methods for treating ischemic stroke in humans, using a tetrafluorobenzyl derivative of formula (I) or a pharmaceutically acceptable salt thereof conjointly with a thrombolytic drug, endovascular thrombectomy, or both (e.g., endovascular thrombectomy and a thrombolytic drug). Administration of a tetrafluorobenzyl derivative of formula (I) or its pharmaceutically acceptable salt can reduce reperfusion injury and other adverse events in patients conjointly receiving a thrombolytic drug, endovascular thrombectomy, or endovascular thrombectomy with a thrombolytic drug.

The invention relates to the technical field of medicines, in particular to application of mulberry bark extract in preparation of medicines for preventing and / or treating ischemia-reperfusion injury, and finds that morusin administration treatment can effectively relieve pathological injury of mouse liver tissue, reduce activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum after hepatic ischemia-reperfusion, and can be used for preparing medicines for preventing and / or treating ischemia-reperfusion injury. The expression of inflammatory cytokines is inhibited, and the proportion of apoptotic cells is remarkably reduced. The invention further finds that the morusin inhibits the expression of 15-hydroxyeicosapentaenoic acid (15-HETE), and the protection effect of the morusin on the HIRI can be reversed by adding the 15-HETE, so that the morusin can be used for inhibiting the expression of the 15-hydroxyeicosapentaenoic acid (15-HETE).

The present application discloses the use of thiolated hyaluronic acid or its salt in myocardial ischemia-reperfusion injury, and belongs to the field of biomedical technology. In this use, the degree of substitution of the synthesized thiolated hyaluronic acid or its salt thiol can reach 10%-40%. The antioxidant capacity of 5mg / ml thiolated hyaluronic acid or its salt can reach more than 50%; in the H9C2 cardiomyocyte SI / RI model, HA-SH can protect H9C2 cardiomyocytes, and can significantly reduce the oxidative stress damage in the SI / RI model; in the constructed rat myocardial ischemia-reperfusion injury model, HA-SH can reduce the oxidative stress damage, apoptosis and inflammatory response caused by myocardial ischemia-reperfusion by regulating the Nrf2 signaling pathway and the HO-1 signaling pathway, reduce the iron mortality rate, and play a role in protecting the heart. The present application provides a new drug development approach, which is of great significance in the field of biomedical technology.

This invention discloses a micropeptide, its encoding nucleic acid, and its application in regulating inflammatory activation of microglia. The amino acid sequence of the micropeptide is shown in SEQ ID NO:3. Simultaneously, this invention discloses the nucleic acid encoding the micropeptide, which contains either the nucleotide sequence shown in SEQ ID NO:1 or the nucleotide sequence shown in SEQ ID NO:2, wherein SEQ ID NO:2 is a small open reading frame located within the sequence of SEQ ID NO:1. This invention validated the translational expression of the micropeptide in microglia by constructing an EGFP reporter gene fusion vector and a SUMO tag fusion expression vector. Functional experiments showed that under oxygen-glucose deprivation / reperfusion injury conditions, the micropeptide significantly inhibited inflammatory activation of microglia. This invention provides a new potential target and candidate drug for the treatment of neuroinflammatory diseases such as stroke.

Compounds, compositions and methods for improving the viability and / or function of cells or for the in vitro, ex vivo or in vivo protection of cells, tissue, graft or organs from various damages are described. The reagents and composition are based on activation of the heat shock response activation and / or the antioxidant response and include for example. HSP90 co-factor inhibitor such as Celastrol or Celastrol analogs used alone or in combination with an adjunct agent (e.g., a NRF-2 activator, antioxidant, etc.). Therapeutic enhancement may also include increase in paracrine effector production and signaling. Methods for improving the resistance of cells, tissue, grafts or organs to damages or stress, such as hypoxic or oxidative stress-induced cell death, and / or for improving the viability and retention of transplanted or transfused cells are also described. Therapeutic treatment or prevention of ischemic injury (e.g. myocardial infarct, ischemia / reperfusion injury) and related stressors (hypoxia, oxidative stress, inflammation, sepsis / shock, etc) are also provided.

Provided is a pharmaceutical composition and application thereof, specifically, said pharmaceutical composition comprises: salvianolic acid B as a first active ingredient; and ginsenoside Rg1 as a second active ingredient, and the weight ratio of the first active ingredient to the second active ingredient being 5:(1-4.5). The pharmaceutical composition has a better active-ingredient proportion than the prior art, has a better therapeutic efficacy in preventing and / or treating ischemic diseases, and ischemia-reperfusion tissue or organ damage, and can be used for treating ischemia and / or ischemia-reperfusion damage of different tissues and organs.

The invention relates to the field of pharmaceutical compositions for promoting atherosclerosis, in particular to a lipid oxide-AGEs composite pharmaceutical composition for promoting atherosclerosis, a method for constructing a rat coronary heart disease ischemia reperfusion injury model by using the composition and application of the composition. The composition comprises 80-90 parts of oxidized lipid, 4-6 parts of 7-ketocholesterol, 2-4 parts of 25-hydroxycholesterol, 8-10 parts of trans-fatty acid, 200-300 parts of an advanced glycosylation end product, 180-220 parts of casein, 320-360 parts of cane sugar, 145-165 parts of corn starch, 45-55 parts of cellulose, 30-40 parts of a mineral mixture, 8-12 parts of a vitamin mixture and 0.4-0.6 mg / kg of folic acid, the vitamin B6 is 1.8 to 2.2 mg / kg, and the vitamin B12 is 0.007 to 0.009 mg / kg.

Methods are provided for the preconditioning, conditioning, or rehabilitation of marginal organs to be used for organ or organ-derived cell transplantation. The methods of the present disclosure contact the marginal organs with a medium or perfusate comprising an effective dose of a Wnt agent. The Wnt agent reduces apoptosis of the cells in the marginal organ while also activating stem cells present in the marginal organ to promote repair, reconditioning, and / or regeneration of the marginal organ. Preconditioning or conditioning of the marginal organ with a Wnt agent reduces the risk of reperfusion injury. In some embodiments, preconditioning of the marginal organ reduces the risk of graft rejection when transplanted into an individual in need thereof.

The invention discloses compounds of Formula (I), wherein the compounds are used as anti-inflammatory agents, for treatment or prevention of a number of diseases or conditions such as atherosclerosis, auto-immune diseases, psoriasis, multiple sclerosis, transplant rejection, asthma, bacterial infection, rhinovirus infection, brain ischemia, ischemia-reperfusion injury, limb ischemia, acute kidney injury, diabetic nephropathy, sepsis, acute respiratory distress syndrome (ARDS), cancer, osteoarthritis, sepsis-induced kidney injury, liver disease, and septic and cardiogenic shock.

Compounds, compositions and methods for improving the viability and / or function of cells or for the in vitro, ex vivo or in vivo protection of cells, tissue, graft or organs from various damages are described. The reagents and composition are based on activation of the heat shock response and / or the antioxidant response and include for example, HSP90 co-factor inhibitor such as Celastrol or Celastrol analogs used alone or in combination with an adjunct agent (e.g., a NRF-2 activator, antioxidant, etc.). Therapeutic enhancement may also include increase in paracrine effector production and signaling. Methods for improving the resistance of cells, tissue, grafts or organs to damages or stress, such as hypoxic or oxidative stress-induced cell death, and / or for improving the viability and retention of transplanted or transfused cells are also described. Therapeutic treatment or prevention of ischemic injury (e.g. myocardial infarct, ischemia / reperfusion injury) and related stressors (hypoxia, oxidative stress, inflammation, sepsis / shock, etc) are also provided.

The invention discloses an application of biotin in preparation of a medicine for treating or preventing ischemia-reperfusion injury, the biotin is applied to intervention research of ischemia-reperfusion injury for the first time, and the protective effect of the biotin in a cell inflammation model and an animal ischemia-reperfusion model is systematically verified. A solid experimental foundation is laid for application of the method in treatment of related diseases such as lung ischemia reperfusion injury and ischemia reperfusion induced pulmonary arterial hypertension, and a brand-new intervention strategy is provided.

The present disclosure relates to an annexin A1 (AnxA1) N-terminal peptide and a pharmaceutical composition comprising such an annexin A1 (AnxA1) N-terminal peptide for use in the treatment of ischemic disorders and / or reperfusion injury.

The invention discloses an ischemia reperfusion injury level analysis method and device. The method comprises the following steps: acquiring a historical multi-sequence medical image generated by cardiac muscle tissue of a to-be-identified object based on nuclear magnetic resonance; the historical multi-sequence medical images are input into a pre-trained damage level analysis model to perform classification prediction and segmentation prediction on the historical multi-sequence medical images, and the pre-trained damage level analysis model is generated based on training of a first training sample used for a classification task and a second training sample used for a segmentation task; outputting a myocardial tissue injury area and a myocardial injury type corresponding to the historical multi-sequence medical image; according to the myocardial injury type and a preset CCS staging standard, the ischemia-reperfusion injury level of the myocardial tissue injury area is determined, and the preset CCS staging standard comprises the mapping relation between the myocardial injury type and the ischemia-reperfusion injury level. Therefore, by adopting the embodiment of the invention, the accuracy of the ischemia reperfusion injury level is improved.

The invention relates to the technical field of biological medicine, in particular to an efficient macrophage targeting vesicle system as well as a preparation method and application thereof. The vesicle system is a chimeric vesicle (mHEs), and is prepared from extracellular vesicles (M2-EVs) derived from M2 type macrophages and apoptotic small bodies (MSC-ABs) derived from bone marrow mesenchymal stem cells. The vesicle system provided by the invention can realize specific recognition and functional regulation of macrophages, thereby playing an efficient therapeutic role in pathological processes such as tissue inflammation repair, myocardial infarction, ischemia-reperfusion injury and immune metabolism remodeling.

The invention belongs to the technical field of nursing vests, and discloses a multi-mode vital sign intelligent nursing vest which comprises a front vest, and a patch opening is formed in the front face of the front vest. By arranging the respiration sensor, the electrocardio sensor, the body temperature sensor and the muscular tension sensor, due to the design of the respiration sensor, the electrocardio sensor, the body temperature sensor and the muscular tension sensor, respiration, electrocardio, body temperature and muscular tension of a patient can be monitored in real time, and monitored data are transmitted to the single chip microcomputer; the single-chip microcomputer monitors vital signs and neurological function changes of a patient in real time through an AI algorithm, automatically warns the risk of encephaledema, epileptic seizure or reperfusion injury, and transmits the monitored vital signs and neurological function changes of the patient to the medical system through the data transmission module. Meanwhile, when it is monitored that the vital signs and the neurological functions of the patient are abnormal, an alarm is given out through the alarm to remind medical staff.